These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12231170)

  • 1. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model.
    Vlachaki MT; Hernandez-Garcia A; Ittmann M; Chhikara M; Aguilar LK; Zhu X; Teh BS; Butler EB; Woo S; Thompson TC; Barrera-Saldana H; Aguilar-Cordova E
    Mol Ther; 2002 Sep; 6(3):342-8. PubMed ID: 12231170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
    Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
    Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
    Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
    Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
    Wang WC; Sayedahmed EE; Mittal SK
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector.
    Gilchrist SC; Ontell MP; Kochanek S; Clemens PR
    Mol Ther; 2002 Sep; 6(3):359-68. PubMed ID: 12231172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy.
    Jiang Z; Feingold E; Kochanek S; Clemens PR
    Mol Ther; 2002 Sep; 6(3):369-76. PubMed ID: 12231173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer.
    Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL
    Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the rat liver, Adenoviral gene transfer efficiency is comparable to AAV.
    Montenegro-Miranda PS; Pichard V; Aubert D; Ten Bloemendaal L; Duijst S; de Waart DR; Ferry N; Bosma PJ
    Gene Ther; 2014 Feb; 21(2):168-74. PubMed ID: 24285217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
    Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A
    Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
    Wortmann A; Vöhringer S; Engler T; Corjon S; Schirmbeck R; Reimann J; Kochanek S; Kreppel F
    Mol Ther; 2008 Jan; 16(1):154-62. PubMed ID: 17848961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
    Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
    Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.
    O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL
    Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.
    Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS
    Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
    Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
    Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.
    Peden CS; Burger C; Muzyczka N; Mandel RJ
    J Virol; 2004 Jun; 78(12):6344-59. PubMed ID: 15163728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
    Ji L; Bouvet M; Price RE; Roth JA; Fang B
    Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors.
    Enger PØ; Thorsen F; Lønning PE; Bjerkvig R; Hoover F
    Hum Gene Ther; 2002 Jun; 13(9):1115-25. PubMed ID: 12067444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.
    Sharma A; Bangari DS; Tandon M; Hogenesch H; Mittal SK
    Virus Res; 2010 Oct; 153(1):134-42. PubMed ID: 20659505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.